VTVT · Insider Trading
vTv Therapeutics Inc. Class A Common Stock
Every open-market purchase and sale reported by VTVT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-29 | Fahed Al-Marzooqi | Director | A | +6,000 deriv. | — |
| 2026-06-29 | Anne M. Phillips | Director | A | +6,000 deriv. | — |
| 2026-06-29 | 667, L.P. | Director | A | +72,000 deriv. | — |
| 2026-06-29 | Daniel K Spiegelman | Director | A | +6,000 deriv. | — |
| 2026-06-29 | Srinivas Akkaraju | Director | A | +6,000 deriv. | — |
| 2026-02-18 | Paul J Sekhri | Pres, CEO and Exec Chairperson | A | +140,000 deriv. | — |
| 2026-02-18 | Michael Stephen Tung | EVP & CFO | A | +44,969 deriv. | — |
| 2025-09-25 | Srinivas Akkaraju | Director | A | +106,000 | +$1.62M |
| 2025-09-05 | Felix Baker | Director | A | +306,000 | — |
| 2025-09-05 | Srinivas Akkaraju | Director | A | +1,311,046 deriv. | — |
| 2025-06-12 | Daniel K Spiegelman | Director | A | +4,000 deriv. | — |
| 2025-06-12 | Srinivas Akkaraju | Director | A | +4,000 deriv. | — |
| 2025-06-12 | Fahed Al-Marzooqi | Director | A | +4,000 deriv. | — |
| 2025-06-12 | Anne M. Phillips | Director | A | +4,000 deriv. | — |
| 2025-06-12 | 667, L.P. | Director | A | +48,000 deriv. | — |
| 2025-05-21 | Michael Stephen Tung | EVP & CFO | A | +45,000 deriv. | — |
| 2025-04-24 | Srinivas Akkaraju | Director | A | +3,233 deriv. | — |
| 2025-03-07 | Paul J Sekhri | Pres, CEO and Exec Chairperson | A | +108,000 deriv. | — |
| 2024-12-06 | Srinivas Akkaraju | Director | D | −58,836 | — |
| 2024-12-06 | Samsara BioCapital GP, LLC | 10%+ Owner | J | −117,672 | — |
| 2024-11-19 | Paul J Sekhri | Pres, CEO and Exec Chairperson | Buy | +5,000 | +$83.81K |
| 2024-06-27 | Anne M. Phillips | Director | A | +3,110 deriv. | — |
| 2024-06-27 | Daniel K Spiegelman | Director | A | +6,000 deriv. | — |
| 2024-06-27 | Fahed Al-Marzooqi | Director | A | +3,000 deriv. | — |
| 2024-06-27 | Baker Brothers Life Sciences LP | Director | A | +83,796 deriv. | — |
| 2024-06-13 | Srinivas Akkaraju | Director | A | +3,750 deriv. | — |
| 2024-06-13 | Fahed Al-Marzooqi | Director | A | +4,055 deriv. | — |
| 2024-06-13 | Paul J Sekhri | President and CEO | A | +89,212 deriv. | — |
| 2024-06-13 | Steven L. Tuch | Chief Financial Officer | A | +62,159 deriv. | — |
| 2024-06-13 | Anne M. Phillips | Director | A | +3,750 deriv. | — |
| 2024-03-07 | Felix Baker | Director | D | −345,942 | — |
| 2024-02-29 | Srinivas Akkaraju | Director | A | +224,732 | +$2.65M |
| 2023-06-21 | Howard L. Weiner | Director | A | +75,000 deriv. | — |
| 2023-06-21 | Keith R. Harris | Director | A | +75,000 deriv. | — |
| 2023-06-21 | Hersh Kozlov | Director | A | +75,000 deriv. | — |
| 2023-06-21 | Fahed Al-Marzooqi | Director | A | +75,000 deriv. | — |
| 2023-06-21 | Chandresh Harjivan | Director | A | +75,000 deriv. | — |
| 2023-06-21 | Jonathan Isaacsohn | Director | — | — | — |
| 2023-06-21 | John A Fry | Director | A | +75,000 deriv. | — |
| 2022-12-13 | Steven L. Tuch | Chief Financial Officer | A | +500,000 deriv. | — |
| 2022-11-30 | John A Fry | Director | Buy | +61,000 | +$50.74K |
| 2022-08-18 | Jonathan Isaacsohn | Director | A | +50,000 deriv. | — |
| 2022-08-17 | Keith R. Harris | Director | A | +25,000 deriv. | — |
| 2022-07-15 | Fahed Al-Marzooqi | Director | A | +25,000 deriv. | — |
| 2022-07-06 | Howard L. Weiner | Director | A | +105,128 deriv. | — |
| 2022-07-06 | Chandresh Harjivan | Director | A | +25,000 deriv. | — |
| 2022-07-06 | Hersh Kozlov | Director | A | +105,128 deriv. | — |
| 2022-07-06 | John A Fry | Director | A | +137,077 deriv. | — |
| 2022-03-04 | Rich S. Nelson | Acting Chief Executive Officer | A | +500,000 deriv. | — |
| 2021-12-21 | Ronald O Perelman | 10%+ Owner | Sell | −87,000 | −$100.05K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Samsara BioCapital GP, LLC | 10%+ Owner | 206,784 | $5.34M |
| Srinivas Akkaraju | Director | 106,000 | $2.74M |
| Felix Baker | Director | 12,368 | $319.22K |
| Paul J Sekhri | Pres, CEO and Exec Chairperson | 5,000 | $129.05K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the VTVT quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.